Ghost-managed medicine : Big Pharma's invisible hands /
Saved in:
| Author / Creator: | Sismondo, Sergio, author. |
|---|---|
| Edition: | First edition. |
| Imprint: | Manchester : Mattering Press, [2018] Baltimore, Md. : Project MUSE, 0000 [2018] |
| Description: | 1 online resource (231 pages) : illustrations |
| Language: | English |
| Subject: | |
| Format: | E-Resource Book |
| URL for this record: | http://pi.lib.uchicago.edu/1001/cat/bib/12491903 |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | 12491903 | ||
| 005 | 20220624111547.0 | ||
| 006 | m o d | ||
| 007 | cr |||||||nn|n | ||
| 008 | 180725s2018 enka ob 000 0 eng d | ||
| 020 | |a 9780995527782 | ||
| 020 | |a 0995527784 | ||
| 020 | |z 0995527776 | ||
| 020 | |z 9780995527775 | ||
| 035 | |a (OCoLC)1229912820 | ||
| 035 | 9 | |a (OCLCCM-CC)1229912820 | |
| 040 | |a P@U |b eng |e pn |c P@U |d OCLCO |d UAB |d WTU |d LIP |d OCL |d YDX |d OCLCQ |d OCLCO | ||
| 049 | |a MAIN | ||
| 050 | 4 | |a HD9665.5 |b .S57 2018eb | |
| 100 | 1 | |a Sismondo, Sergio, |e author. |0 http://id.loc.gov/authorities/names/n95030311 | |
| 245 | 1 | 0 | |a Ghost-managed medicine : |b Big Pharma's invisible hands / |c Sergio Sismondo. |
| 250 | |a First edition. | ||
| 264 | 1 | |a Manchester : |b Mattering Press, |c [2018] | |
| 264 | 3 | |a Baltimore, Md. : |b Project MUSE, |c 0000 | |
| 264 | 4 | |c [2018] | |
| 300 | |a 1 online resource (231 pages) : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 504 | |a Includes bibliographical references (pages 195-231). | ||
| 588 | 0 | |a Print version record and online resource, viewed February 22, 2021. | |
| 520 | |a "Ghost-Managed Medicine by Sergio Sismondo explores a spectral side of medical knowledge, based in pharmaceutical industry tactics and practices. Hidden from the public view, the many invisible hands of the pharmaceutical industry and its agents channel streams of drug information and knowledge from contract research organizations (that extract data from experimental bodies) to publication planners (who produce ghostwritten medical journal articles) to key opinion leaders (who are sent out to educate physicians about drugs) to patient advocacy organizations (who ventriloquize views on diseases, treatments and regulations), and onward. The goal of this 'assemblage marketing' is to establish conditions that make specific diagnoses, prescriptions and purchases as obvious and frequent as possible. While staying in the shadows, companies create powerful markets in which increasing numbers of people become sick and the drugs largely sell themselves ... Ghost-Managed Medicine draws on presentations at industry conferences, especially ones where pharmaceutical companies interact with communication, marketing and other agencies. Participants at these interface conferences describe goals, practices and concerns; in the process, they reveal a lot about how the industry works. Some of the book's other data is taken from publications that also serve as interfaces between the industry and adjacent actors, and from interviews with people engaged in pharmaceutical marketing"--Publisher's description | ||
| 505 | 0 | |a 1. Power and Knowledge in Drug Marketing -- 2. Data Extraction at the Margins of Health -- 3. Ghosts in the Machine: Publication Planning -- 4. Hosts and Guests in the Haunted House -- 5. Possession: Making and Managing Key Opinion Leaders -- 6. Draining and Constraining Agency -- 7. Sirens of Hope, Trolls of Fury and Other Vocal Creatures -- 8. Conclusion : The Haunted Pharmakon. | |
| 650 | 0 | |a Drugs |x Research |x Moral and ethical aspects. | |
| 650 | 0 | |a Drugs |x Marketing |x Moral and ethical aspects. | |
| 650 | 0 | |a Pharmaceutical industry |x Influence. | |
| 650 | 0 | |a Pharmaceutical industry |x Moral and ethical aspects. | |
| 650 | 6 | |a Médicaments |x Recherche |x Aspect moral. | |
| 650 | 6 | |a Industrie pharmaceutique |x Influence. | |
| 650 | 6 | |a Industrie pharmaceutique |x Aspect moral. | |
| 650 | 7 | |a Pharmaceutical industry |x Moral and ethical aspects. |2 fast |0 (OCoLC)fst01060163 | |
| 650 | 7 | |a Drugs |x Research |x Moral and ethical aspects. |2 fast |0 (OCoLC)fst00898905 | |
| 650 | 7 | |a Drugs |x Marketing |x Moral and ethical aspects. |2 fast |0 (OCoLC)fst00898841 | |
| 655 | 4 | |a Electronic books. | |
| 856 | 4 | 0 | |u https://muse.jhu.edu/book/81376 |y Project Muse |
| 856 | 4 | 0 | |u https://directory.doabooks.org/handle/20.500.12854/48607 |y Open Access Publishing in European Networks |
| 903 | |a HeVa | ||
| 929 | |a oclccm | ||
| 999 | f | f | |i c3c85dd0-723c-5fa3-b05a-c98437423d17 |s cc1694a3-cccf-54da-9e48-fda62d347c55 |
| 928 | |t Library of Congress classification |a HD9665.5.S57 2018eb |l Online |c UC-FullText |u https://muse.jhu.edu/book/81376 |z Project Muse |u https://directory.doabooks.org/handle/20.500.12854/48607 |z Open Access Publishing in European Networks |g ebooks |i 12120969 | ||